Cholesterol Microdomain Enhances the Biofilm Eradication of Antibiotic Liposomes

Adv Healthc Mater. 2022 Apr;11(8):e2101745. doi: 10.1002/adhm.202101745. Epub 2022 Jan 27.

Abstract

Resistance and tolerance of biofilms to antibiotics is the greatest challenge in the treatment of bacterial infections. Therefore, developing an effective strategy against biofilms is a top priority. Liposomes are widely used as antibiotic drug carriers; however, common liposomes lack affinity for biofilms. Herein, biofilm-targeted antibiotic liposomes are created by simply adjusting their cholesterol content. The tailored liposomes exhibit significantly enhanced bacterial inhibition and biofilm eradication effects that are positively correlated with the cholesterol content of liposomes. The experiments further demonstrate that this enhanced effect can be ascribed to the effective drug release through the pores, which are formed by the combination of cholesterol microdomains in liposomal lipid bilayers with membrane-damaged toxins in biofilms. Consequently, liposome encapsulation with a high cholesterol concentration improves noticeably the pharmacodynamics and biocompatibility of antibiotics after pulmonary administration. This work may provide a new direction for the development of antibiofilm formulations that can be widely used for the treatment of infections caused by bacterial biofilms.

Keywords: Staphylococcus aureus; berberine liposomes; biofilms; cholesterol; inhaled administration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Biofilms
  • Cholesterol
  • Drug Carriers / pharmacology
  • Liposomes* / pharmacology
  • Microbial Sensitivity Tests

Substances

  • Anti-Bacterial Agents
  • Drug Carriers
  • Liposomes
  • Cholesterol